Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504697 · ClinicalTrials.gov registry record
DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer
A clinical trial of Pulmonary Disease, sponsored by Boston University.
- Active
- Registry status
- 665
- Enrollment target
- 15
- Study locations
NCT02504697 is a study of Pulmonary Disease that is active but no longer recruiting, run by Boston University. The registered enrollment target is 665 participants, above the 590-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (13% higher). The trial reports 15 study locations across 9 states.
The verdict
NCT02504697, a study of Pulmonary Disease, is active but no longer recruiting, sponsored by Boston University.
- ACTIVE NOT RECRUITING
- Registry status
- 665 participants
- Enrollment target
- 15
- Study locations
Study Summary
The goal of this project is to improve lung cancer screening in high-risk individuals by identifying biomarkers of preclinical disease and disease risk that are measured in minimally invasive and non-invasive biospecimens. Existing biomarkers for lung cancer diagnosis as well as new biomarkers discovered specifically in this clinical setting will be examined. Biomarkers that identify individuals at highest risk for being diagnosed with lung cancer prior to the appearance of concerning symptoms could increase the utility of lung cancer surveillance and the efficiency of lung cancer chemoprevention clinical trials. Achieving these goals would improve the detection and treatment of early stage and incipient lung cancer, while restricting the risk of these procedures to those individuals who currently exhibit the early molecular warning signs of impending disease.
Conditions Studied
Interventions
- OTHER Biosamples from airway and blood
Study Locations (15)
California
- Regents of the University of California LA (Los Angeles VA Healthcare System) - Los Angeles
- University of California Los Angeles Medical Center - Los Angeles
- Naval Medical Center San Diego - San Diego
Pennsylvania
- Trustees of University of Pennsylvania (Philadelphia VA Medical Center) - Philadelphia
- University of Pennsylvania - Philadelphia
- Veterans Research Foundation of Pittsburgh - Pittsburgh
Massachusetts
- Boston University Medical Center - Boston
- Boston VA Research Institute, Inc - Boston
Texas
- Dallas VA Research Corporation - Dallas
- San Antonio Military Medical Center - San Antonio
Colorado
- Denver Research Institute - Denver
Maryland
- Walter Reed National Military Medical Center - Bethesda
New York
- Health Research Inc. Roswell Park Division - Buffalo
Tennessee
- Middle Tennessee Research Institute (Vanderbilt University) - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2011-09 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02504697
The ClinicalTrials.gov registry entry for NCT02504697 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 665 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 590-participant average among 19 other Pulmonary Disease trials with a reported enrollment target (13% higher). The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Biosamples from airway and blood is the first listed.
NCT02504697 reports 15 study locations spanning 9 distinct geographic areas - top geographies include California, Pennsylvania, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02504697 about?
NCT02504697 is a clinical study titled "DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer". The goal of this project is to improve lung cancer screening in high-risk individuals by identifying biomarkers of preclinical disease and disease risk that are measured in minimally invasive and non-invasive biospecimens. Existing biomarkers for lung cancer diagnosis as well as new biomarkers disco...
What is the current status of trial NCT02504697?
This trial is currently active not recruiting. The enrollment target is 665 participants. The study started on 2011-09. Estimated completion is 2027-12.
What conditions does trial NCT02504697 study?
This clinical trial studies the following conditions: Pulmonary Disease.
What interventions are being tested in trial NCT02504697?
The interventions under investigation include: Biosamples from airway and blood (OTHER).
Who is sponsoring clinical trial NCT02504697?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02504697 being conducted?
This trial has 15 study locations across California, Colorado, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections
RECRUITING
-
Quantitative Pulmonary Imaging Registry & Biorepository
RECRUITING
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
Study of Lung Proteins in Patients With Pneumonia
RECRUITING
-
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
RECRUITING
-
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.